109 Zina Pitcher Pl, 4021 BSRB
Ann Arbor, Michgan 48109-2200
Available to mentor
Dr. Callaghan is a Professor of Neurology and a neuromuscular specialist at the University of Michigan. He completed his medical degree and neurology residency at the University of Pennsylvania and completed a fellowship in neuromuscular disease at the University of Michigan. He also completed a master’s degree program in clinical research at the University of Michigan School of Public Health.
-
FellowshipCenter for Healthcare Research and Transformation Policy, University of Michigan, Ann Arbor, Michigan, 2016
-
FellowshipUniversity of Michigan Health System, Neuromuscular, 2009
-
ResidencyUniversity of Pennsylvania Medical Center, Neurology, 2008
-
Internship, Preliminary MedicineUniversity of Pennsylvania Medical Center, Philadelphia, Pennsylvania, 2005
-
MSUniversity of Michigan, Ann Arbor, 2011
-
MDUniversity of Pennsylvania Medical Center, 3400 Spruce Street, 2004
-
BSUniversity of Michigan, Ann Arbor, 1999
-
Center MemberCaswell Diabetes Institute
-
Center MemberInstitute for Healthcare Policy and Innovation
Dr. Callaghan is interested in the treatment of painful diabetic neuropathy and other chronic pain conditions including the role of opioids. He has led the recent American Academy of Neurology guideline on the treatment of painful diabetic neuropathy and is interested in better understanding the best interventions for this common condition. Furthermore, Dr. Callaghan is interested in a better understanding of the appropriate role of opioids in chronic non cancer pain conditions.
-
Reynolds EL, Watanabe M, Banerjee M, Chant E, Villegas-Umana E, Elafros MA, Gardner TW, Pop-Busui R, Pennathur S, Feldman EL, Callaghan BC. Diabetologia, 2023 Jul; 66 (7): 1192 - 1207.Journal ArticleThe effect of surgical weight loss on diabetes complications in individuals with class II/III obesity.
DOI:10.1007/s00125-023-05899-3 PMID: 36917280 -
Elafros MA, Reynolds EL, Callaghan BC. Curr Opin Neurol, 2024 Oct 1; 37 (5): 467 - 477.Journal ArticleObesity-related neuropathy: the new epidemic.
DOI:10.1097/WCO.0000000000001292 PMID: 38864534 -
Watanabe M, Reynolds EL, Banerjee M, Charles M, Mizokami-Stout K, Albright D, Ang L, Lee JM, Pop-Busui R, Feldman EL, Callaghan BC. Diabetes Care, 2024 Sep 1; 47 (9): 1638 - 1646.Journal ArticleBidirectional Associations Between Mental Health Disorders and Chronic Diabetic Complications in Individuals With Type 1 or Type 2 Diabetes.
DOI:10.2337/dc24-0818 PMID: 39008530 -
Chen C-S, Dorsch MP, Alsomairy S, Griggs JJ, Jagsi R, Sabel M, Stino A, Callaghan B, Hertz DL. JMIR Preprints,PreprintRemote Monitoring of Chemotherapy-Induced Peripheral Neuropathy via NeuroDetect iOS App (Preprint)
DOI:10.2196/preprints.65615 -
Merino JG, Ciccarelli O, Barkhof F, Burch R, Callaghan BC, Hedera P, Hershey LA, Jobst BC, Schneider AL, Worrall BB, Wusthoff CJ. Neurology, 2024 Jul 9; 103 (1): e209642Journal ArticleMessage From the Editors to Our Reviewers.
DOI:10.1212/WNL.0000000000209642 PMID: 38830177 -
Lin CC, Callaghan B. Neurology, 2024 Jul 23; 103 (2): e209434Journal ArticleAuthor Response: Patient Travel Distance to Neurologist Visits.
DOI:10.1212/WNL.0000000000209434 PMID: 38885480 -
Elafros M, Reynolds E, Callaghan B. Current Opinion in Neurology, 2024 Jun 13; doi: 10-1097/WCO.000000000001292:Journal ArticleObesity-related neuropathy: the new epidemic
-
Kristensen FPB, Christensen DH, Callaghan BC, Nielsen JS, Højlund K, Andersen H, Dekkers OM, Groenwold RHH, Sørensen HT, Thomsen RW. Neurology, 2024 Jul 9; 103 (1): e209538Journal ArticleLipid Levels and Risk of Diabetic Polyneuropathy in 2 Danish Type 2 Diabetes Cohorts.
DOI:10.1212/WNL.0000000000209538 PMID: 38833657